Free Stock Performance Review on Biogen and Three Additional Biotech Stocks

Stock Research Monitor: BDSI, BHVN, and CERS

LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on BIIB sign up now at www.wallstequities.com/registration. This morning, WallStEquities.com observes BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), Biogen Inc. (NASDAQ: BIIB), and Cerus Corp. (NASDAQ: CERS). The Biotechnology industry consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

BioDelivery Sciences International

Raleigh, North Carolina headquartered BioDelivery Sciences International Inc.’s stock finished Monday’s session 2.75% lower at $2.65 with a total trading volume of 200,672 shares. Over the previous three months, the Company’s shares have advanced 32.50%. The stock is trading above its 200-day moving average by 5.54%. Moreover, shares of the Company, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have a Relative Strength Index (RSI) of 41.32.

On July 24th, 2018, BioDelivery Sciences International announced that it will report its Q2 2018 financial results after the close of the US Financial markets on Thursday, August 09th, 2018. The Company will host a conference call at 4:30 p.m. ET on the same day to discuss the results and provide an update on its business operations. Get the full research report on BDSI for free by clicking below at:

www.wallstequities.com/registration/?symbol=BDSI

Biohaven Pharmaceutical Holding

Shares in New Haven, Connecticut-based Biohaven Pharmaceutical Holding Co. Ltd declined 1.62%, ending yesterday’s session at $33.32 with a total trading volume of 232,970 shares. The stock has gained 14.27% in the previous three months and 30.11% over the past year. The Company’s shares are trading 9.35% above their 200-day moving average. Moreover, shares of Biohaven Pharma, which develops product candidates to treat neurological diseases, including rare disorders, have an RSI of 31.93.

On July 03rd, 2018, research firm Needham reiterated its ‘Buy’ rating on the Company’s stock with an increase of the target price from $36 a share to $48 a share.

On July 24th, 2018, Biohaven Pharma announced that it initiated a Phase-2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator, in patients with mild-to-moderate Alzheimer’s disease (AD). The trial is being conducted in collaboration with the Alzheimer’s Disease Cooperative Study, as previously announced. The first AD patient is expected to enroll in the coming weeks. Find your free research report on BHVN at:

www.wallstequities.com/registration/?symbol=BHVN

Biogen

On Monday, Cambridge, Massachusetts headquartered Biogen Inc.’s stock dropped 2.63%, to close the day at $331.46. A total volume of 2.37 million shares was traded, which was above their three months average volume of 1.95 million shares. The Company’s shares have advanced 14.79% in the last month, 21.15% in the previous three months, and 15.31% over the past year. The stock is trading 5.72% and 7.89% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Biogen, which discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide, have an RSI of 47.49.

On July 25th, 2018, research firm SunTrust reiterated its ‘Buy’ rating on the Company’s stock with an increase of the target price from $321 a share to $392 a share.

On July 25th, 2018 at the Alzheimer’s Association International Conference (AAIC) 2018 in Chicago, Illinois, Biogen and Eisai Co., Ltd announced detailed results from the Phase-II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer’s disease. This abstract was accepted for Late Breaking oral presentation at AAIC. Sign up today for the free research report on BIIB at:

www.wallstequities.com/registration/?symbol=BIIB

Cerus

Shares in Concord, California headquartered Cerus Corp. ended the day 1.91% lower at $7.18. A total volume of 714,840 shares was traded. The stock has gained 5.59% in the last month, 38.08% in the previous three months, and 217.70% over the past year. The Company’s shares are trading above their 50-day and 200-day moving averages by 3.48% and 43.41%, respectively. Furthermore, shares of Cerus, which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety, have an RSI of 48.87.

On July 19th, 2018, Cerus announced that its Q2 results will be released on August 02nd, 2018, after the close of the stock market. The Company will host a conference call and webcast at 4:15 p.m. EDT that afternoon, during which management will discuss the results and provide a general business overview and outlook. The live webcast may be accessed under the Investor Relations page of the Company’s website. Wall St. Equities’ research coverage also includes the downloadable free report on CERS at:

www.wallstequities.com/registration/?symbol=CERS

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507479